仿生阿霉素/人参皂苷共载纳米系统用于急性髓系白血病的化免疫治疗。
Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia.
机构信息
Department of Pharmaceutics, China Pharmaceutical University, Xuanwumen Campus, No.24, Tongjiaxiang, Gulou District, Nanjing, 210009, Jiangsu province, China.
Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
出版信息
J Nanobiotechnology. 2022 Jun 14;20(1):273. doi: 10.1186/s12951-022-01491-w.
BACKGROUND
Acute myeloid leukemia (AML) showed limited clinical therapeutic efficiency with chemotherapy for its multi-distributed lesions and hard-to-kill leukemia cells deep in the bone marrow.
RESULTS
Here, a biomimetic nanosystem (DR@PLip) based on platelet membrane (PM) coating and doxorubicin (DOX)/ginsenoside (Rg3) co-loading was developed to potentiate the local-to-systemic chemoimmunotherapy for AML. The PM was designed for long-term circulation and better leukemia cells targeting. The participation of Rg3 was proved to enhance the tumor sensitivity to DOX, thus initiating the anti-tumor immune activation and effectively combating the leukemia cells hiding in the bone marrow.
CONCLUSIONS
In conclusion, the strategy that combining immediate chemotherapy with long-term immunotherapy achieved improved therapeutic efficiency and prolonged survival, which provided a new perspective for the clinical treatment of AML.
背景
急性髓系白血病（AML）由于其多发性病变和骨髓深处难以杀灭的白血病细胞，化疗的临床治疗效果有限。
结果
本研究构建了一种基于血小板膜（PM）包覆和阿霉素（DOX）/人参皂苷 Rg3 共载的仿生纳米系统（DR@PLip），以增强 AML 的局部-系统化疗免疫治疗效果。PM 设计用于延长循环时间和更好地靶向白血病细胞。Rg3 的参与被证明可以增强肿瘤对 DOX 的敏感性，从而启动抗肿瘤免疫激活，并有效对抗隐藏在骨髓中的白血病细胞。
结论
综上所述，联合即刻化疗和长期免疫治疗的策略提高了治疗效果并延长了生存期，为 AML 的临床治疗提供了新视角。
Zotero 插件